Effectiveness of Nurse-Led Interventions in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis.

J Clin NursMay 7, 2026 (epub)
Clinical ResearchGeriatricsPsychiatryOpen access

Wei Xu, Guangwei Zhang, Xuechun Bai et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of nurse-led interventions in older adults with mild cognitive impairment or dementia. The analysis revealed that these interventions significantly improved cognitive function (SMD = 0.64; 95% CI, 0.39-0.88; p < 0.05), reduced depressive symptoms, and enhanced quality of life.

Key findings

  • Nurse-led interventions improved cognitive function with a standardized mean difference of 0.64.
  • Depressive symptoms were significantly alleviated with a standardized mean difference of -0.32.
  • Quality of life was enhanced with a standardized mean difference of 0.40.

Why it matters

As cognitive impairment becomes increasingly prevalent, understanding the role of nurse-led interventions is crucial for improving patient outcomes in this population. Effective management can enhance quality of life and reduce depressive symptoms.

Source

PubMed · PMID 42098971Free full text on PubMed Central

Published in J Clin Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.